Characteristics and outcomes of the cohort of patients who received allogeneic HSCTs at FHCRC, 1993-1998 (n = 1682)
| . | No. (%) . |
|---|---|
| Median recipient age, y (range) | 37 (0-68) |
| Male sex | 1013 (60.2) |
| Underlying diagnosis | |
| CML, chronic phase | 404 (24.0) |
| Hematologic malignancy, first remission | 166 (9.9) |
| Hematologic malignancy, other | 729 (43.3) |
| Other | 383 (22.8) |
| Donor and stem cell source | |
| MR BM | 566 (33.7) |
| MR PBSCs | 192 (11.4) |
| MM/UR BM | 882 (52.4) |
| MM/UR PBSCs | 29 (1.7) |
| Cord blood | 13 (0.8) |
| T cell–depleted/CD34-selected | 70 (4.2) |
| CMV serostatus* | |
| D−/R− | 571 (34.2) |
| D+/R− | 252 (15.1) |
| D−/R+ | 366 (21.9) |
| D+/R+ | 483 (28.9) |
| CMV disease | 166 (9.9) |
| GVHD, acute grade higher than 1 | 1207 (77.2) |
| GVHD, clinically extensive | 696 (59.0) |
| Respiratory virus infection | 280 (16.7) |
| Delayed neutrophil engraftment | 973 (57.9) |
| Delayed lymphocyte engraftment | 1123 (66.8) |
| Delayed monocyte engraftment | 1162 (69.1) |
| Secondary neutropenia | 170 (10.1) |
| . | No. (%) . |
|---|---|
| Median recipient age, y (range) | 37 (0-68) |
| Male sex | 1013 (60.2) |
| Underlying diagnosis | |
| CML, chronic phase | 404 (24.0) |
| Hematologic malignancy, first remission | 166 (9.9) |
| Hematologic malignancy, other | 729 (43.3) |
| Other | 383 (22.8) |
| Donor and stem cell source | |
| MR BM | 566 (33.7) |
| MR PBSCs | 192 (11.4) |
| MM/UR BM | 882 (52.4) |
| MM/UR PBSCs | 29 (1.7) |
| Cord blood | 13 (0.8) |
| T cell–depleted/CD34-selected | 70 (4.2) |
| CMV serostatus* | |
| D−/R− | 571 (34.2) |
| D+/R− | 252 (15.1) |
| D−/R+ | 366 (21.9) |
| D+/R+ | 483 (28.9) |
| CMV disease | 166 (9.9) |
| GVHD, acute grade higher than 1 | 1207 (77.2) |
| GVHD, clinically extensive | 696 (59.0) |
| Respiratory virus infection | 280 (16.7) |
| Delayed neutrophil engraftment | 973 (57.9) |
| Delayed lymphocyte engraftment | 1123 (66.8) |
| Delayed monocyte engraftment | 1162 (69.1) |
| Secondary neutropenia | 170 (10.1) |
Only patients who received myeloablative conditioning regimens between January 1, 1993, and December 31, 1998, were included in the cohort. Cohort does not include patients who developed IA prior to HSC transplantation. Characteristics and outcome variables shown are those that were examined in risk factor models.
BM indicates bone marrow; PBSCs, peripheral blood stem cells; MM, mismatched; and UR, unrelated.
CMV serostatus was not available for 10 patient-donor pairs.